SG11201707246YA - Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof - Google Patents
Fluorinated lysyl oxidase-like 2 inhibitors and uses thereofInfo
- Publication number
- SG11201707246YA SG11201707246YA SG11201707246YA SG11201707246YA SG11201707246YA SG 11201707246Y A SG11201707246Y A SG 11201707246YA SG 11201707246Y A SG11201707246Y A SG 11201707246YA SG 11201707246Y A SG11201707246Y A SG 11201707246YA SG 11201707246Y A SG11201707246Y A SG 11201707246YA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- lysyl oxidase
- fluorinated
- fluorinated lysyl
- oxidase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562129543P | 2015-03-06 | 2015-03-06 | |
PCT/US2016/020732 WO2016144703A1 (en) | 2015-03-06 | 2016-03-03 | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201707246YA true SG11201707246YA (en) | 2017-10-30 |
Family
ID=56879638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201707246YA SG11201707246YA (en) | 2015-03-06 | 2016-03-03 | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
Country Status (15)
Country | Link |
---|---|
US (3) | US10150732B2 (ko) |
EP (2) | EP3265456B1 (ko) |
JP (1) | JP6697809B2 (ko) |
KR (1) | KR102594441B1 (ko) |
CN (1) | CN107592861B (ko) |
AU (2) | AU2016229268B2 (ko) |
BR (1) | BR112017019150B1 (ko) |
CA (1) | CA2977947A1 (ko) |
EA (1) | EA034891B1 (ko) |
ES (1) | ES2838977T3 (ko) |
IL (1) | IL254236A0 (ko) |
MX (1) | MX2017011269A (ko) |
PH (1) | PH12017501611A1 (ko) |
SG (1) | SG11201707246YA (ko) |
WO (1) | WO2016144703A1 (ko) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3265456B1 (en) | 2015-03-06 | 2020-11-18 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
WO2016144702A1 (en) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
GB201602934D0 (en) | 2016-02-19 | 2016-04-06 | Cancer Res Inst Royal | Compounds |
KR102615565B1 (ko) * | 2016-09-07 | 2023-12-18 | 파마케아, 인크. | 리실 옥시다제 유사 2 억제제의 용도 |
EA201990621A1 (ru) | 2016-09-07 | 2019-09-30 | Фармакеа, Инк. | Кристаллические формы ингибитора лизилоксидаза-подобного белка 2 и способы получения |
JP2019529387A (ja) * | 2016-09-07 | 2019-10-17 | ファーマケア,インク. | リシルオキシダーゼ様2の化学プローブおよびその使用 |
TWI775823B (zh) * | 2017-03-17 | 2022-09-01 | 日商Mmag股份有限公司 | 植物病害防治劑 |
CN110128355A (zh) * | 2018-01-17 | 2019-08-16 | 苏州鹏旭医药科技有限公司 | 一种含有6-甲基尿嘧啶结构化合物的制备方法 |
EP3720845A4 (en) * | 2017-12-05 | 2021-09-01 | Suzhou Pengxu Pharmatech Co., Ltd. | ELAGOLIX PRODUCTION PROCESS |
WO2019168847A1 (en) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
KR20210049090A (ko) | 2018-07-05 | 2021-05-04 | 인사이트 코포레이션 | A2a/a2b 억제제로서 융합된 피라진 유도체 |
AU2019315330A1 (en) * | 2018-08-03 | 2021-01-21 | Pharmaxis Ltd. | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof |
GB201818750D0 (en) | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
CA3145738A1 (en) * | 2019-07-25 | 2021-01-28 | Pharmaxis Ltd. | Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof |
TW202132281A (zh) | 2019-11-06 | 2021-09-01 | 南韓商柳韓洋行股份有限公司 | 吡咯啶及哌啶類化合物 |
WO2021216592A1 (en) * | 2020-04-21 | 2021-10-28 | Anovia Biosciences, Inc. | Lox enzyme inhibiting methods and compositions |
EP4173639A4 (en) | 2020-06-26 | 2024-03-13 | RaQualia Pharma Inc. | METHOD FOR SELECTING A CANCER PATIENT WITH EFFECT OF COMBINATION THERAPY WITH RETINOID AND CANCER TREATMENT |
KR102608183B1 (ko) * | 2021-03-11 | 2023-11-30 | 연세대학교 산학협력단 | 신규한 인돌라진 유도체 및 이를 포함하는 암의 예방 또는 치료용 조성물 |
KR102631074B1 (ko) * | 2021-04-09 | 2024-01-30 | 연세대학교 산학협력단 | 신규한 인돌라진 유도체 및 이를 포함하는 섬유증의 예방 또는 치료용 조성물 |
GB202209622D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Compounds |
GB202209624D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Prodrugs |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1015073A (en) | 1911-06-19 | 1912-01-16 | Ley P Rexford | Knockdown brooder. |
US1077406A (en) | 1912-03-18 | 1913-11-04 | Edward Hixon | Apparatus for treating water. |
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
IE56702B1 (en) | 1982-12-01 | 1991-11-06 | Usv Pharma Corp | Antiinflammatory antiallergic compounds |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
FI890827A (fi) * | 1988-02-25 | 1989-08-26 | Merrell Dow Pharma | Lysyloxidas-inhibitorer. |
US5021456A (en) * | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
US5250532A (en) | 1991-04-11 | 1993-10-05 | Dowelanco | 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides |
US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
US6956047B1 (en) | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
US7125880B1 (en) | 1995-06-06 | 2006-10-24 | Pfizer Inc. | Corticotropin releasing factor antagonists |
US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
EA200200688A1 (ru) | 2000-01-18 | 2003-02-27 | Пфайзер Продактс Инк. | Антагонисты фактора, высвобождающего кортикотропин |
US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
CN1787817B (zh) | 2003-05-19 | 2011-09-07 | Irm责任有限公司 | 免疫抑制剂化合物及组合物 |
WO2007016784A1 (en) | 2005-08-11 | 2007-02-15 | Merck Frosst Canada Ltd. | Novel substituted 1,2,3-tπazolylmethyl-benzothiophene or -indole and their use as leukotπene biosynthesis inhibitors |
CA2555172A1 (en) | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders |
CA2558568A1 (en) | 2004-03-12 | 2005-09-29 | Eli Lilly And Company | Opioid receptor antagonists |
ES2379362T3 (es) | 2004-03-15 | 2012-04-25 | Eli Lilly And Company | Antagonistas del receptor opioide |
AU2005238386A1 (en) | 2004-04-30 | 2005-11-10 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof as an MMP-13 inhibitor |
US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
US20080318926A1 (en) | 2004-09-10 | 2008-12-25 | Pfizer Inc | Methods of Treating Mood Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives |
WO2006027692A2 (en) | 2004-09-10 | 2006-03-16 | Pfizer Products Inc. | Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives |
US20080004269A1 (en) | 2004-11-04 | 2008-01-03 | Yuelian Xu | Pyrazolylmethy Heteroaryl Derivatives |
DE102004056226A1 (de) * | 2004-11-22 | 2006-05-24 | Burchardt, Elmar Reinhold, Dr.Dr. | Neuartige Inhibitoren der Lysyloxidase |
ATE440091T1 (de) | 2005-01-31 | 2009-09-15 | Merck & Co Inc | Antidiabetische bicyclische verbindungen |
AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
ITMI20051943A1 (it) | 2005-10-14 | 2007-04-15 | Procos Spa | Processo di risoluzione anantiomerica di 2-aminometil-pirrolidine 1-sostitute per ammidazione in presenza di lipasi |
US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
MX2008009475A (es) | 2006-01-23 | 2008-10-20 | Amira Pharmaceuticals Inc | Inhibidores triciclicos de 5-lipoxigenasa. |
GB0614579D0 (en) | 2006-07-21 | 2006-08-30 | Black James Foundation | Pyrimidine derivatives |
EP2121703A4 (en) | 2006-08-18 | 2011-12-28 | Astrazeneca Ab | THIENOPYRIMIDIN-4-ON- AND THIENOPYRIDAZIN-7-ONDERIVATES AS MCH-RL ANTAGONISTS |
IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
JP5659014B2 (ja) | 2007-08-02 | 2015-01-28 | ジリード バイオロジクス,インク. | 線維症、腫瘍浸潤、血管新生及び転移の治療及び診断のための方法及び組成物 |
US8343944B2 (en) | 2009-07-28 | 2013-01-01 | Anacor Pharmaceuticals, Inc. | Trisubstituted boron-containing molecules |
WO2011022710A1 (en) | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | Therapeutic methods and compositions |
RU2549684C2 (ru) | 2010-02-04 | 2015-04-27 | Джилид Байолоджикс, Инк. | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения |
WO2011097594A2 (en) | 2010-02-08 | 2011-08-11 | Kinagen, Inc. | Therapeutic methods and compositions involving allosteric kinase inhibition |
WO2011109799A1 (en) * | 2010-03-05 | 2011-09-09 | Karyopharm Therapeutics, Inc. | Nuclear transport modulatiors and uses thereof |
WO2011150201A2 (en) | 2010-05-27 | 2011-12-01 | Ambit Biosciences Corporation | Azolyl amide compounds and methods of use thereof |
EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
AU2011329734B2 (en) * | 2010-11-19 | 2015-05-28 | Incyte Holdings Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
TW201313721A (zh) * | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
JP6073343B2 (ja) * | 2011-10-20 | 2017-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ |
JP6175673B2 (ja) * | 2012-04-25 | 2017-08-09 | ラクオリア創薬株式会社 | Ttx−s遮断薬としてのアミド誘導体 |
CN107982531A (zh) | 2012-10-30 | 2018-05-04 | 吉利德科学公司 | 与赖氨酰氧化酶样蛋白2 (loxl2)相关的治疗和诊断方法 |
WO2014098098A1 (ja) | 2012-12-18 | 2014-06-26 | 味の素株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
CA2939655A1 (en) | 2014-02-14 | 2016-02-11 | The University Of British Columbia | Modulators of caspase-6 |
US9051320B1 (en) | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
PT3256463T (pt) | 2015-02-15 | 2019-12-05 | Hoffmann La Roche | Derivados de 1-(het)arilsulfonil-(pirrolidina ou piperidina)-2-carboxamida e a sua utilização como antagonistas do trpa1 |
WO2016144702A1 (en) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
EP3265456B1 (en) | 2015-03-06 | 2020-11-18 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
KR102615565B1 (ko) | 2016-09-07 | 2023-12-18 | 파마케아, 인크. | 리실 옥시다제 유사 2 억제제의 용도 |
EA201990621A1 (ru) | 2016-09-07 | 2019-09-30 | Фармакеа, Инк. | Кристаллические формы ингибитора лизилоксидаза-подобного белка 2 и способы получения |
-
2016
- 2016-03-03 EP EP16762186.1A patent/EP3265456B1/en active Active
- 2016-03-03 MX MX2017011269A patent/MX2017011269A/es active IP Right Grant
- 2016-03-03 EP EP20205649.5A patent/EP3795568A1/en active Pending
- 2016-03-03 CN CN201680026215.8A patent/CN107592861B/zh active Active
- 2016-03-03 SG SG11201707246YA patent/SG11201707246YA/en unknown
- 2016-03-03 WO PCT/US2016/020732 patent/WO2016144703A1/en active Application Filing
- 2016-03-03 KR KR1020177027501A patent/KR102594441B1/ko active IP Right Grant
- 2016-03-03 BR BR112017019150-4A patent/BR112017019150B1/pt active IP Right Grant
- 2016-03-03 CA CA2977947A patent/CA2977947A1/en active Pending
- 2016-03-03 JP JP2017543746A patent/JP6697809B2/ja active Active
- 2016-03-03 EA EA201791874A patent/EA034891B1/ru not_active IP Right Cessation
- 2016-03-03 ES ES16762186T patent/ES2838977T3/es active Active
- 2016-03-03 AU AU2016229268A patent/AU2016229268B2/en not_active Ceased
-
2017
- 2017-08-31 IL IL254236A patent/IL254236A0/en unknown
- 2017-09-05 US US15/695,911 patent/US10150732B2/en active Active
- 2017-09-06 PH PH12017501611A patent/PH12017501611A1/en unknown
-
2018
- 2018-09-21 US US16/138,680 patent/US10570094B2/en active Active
-
2019
- 2019-12-13 US US16/713,314 patent/US11072585B2/en active Active
-
2020
- 2020-08-24 AU AU2020220225A patent/AU2020220225A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112017019150B1 (pt) | 2023-05-09 |
US20190119211A1 (en) | 2019-04-25 |
WO2016144703A1 (en) | 2016-09-15 |
AU2016229268A1 (en) | 2017-09-21 |
JP2018512381A (ja) | 2018-05-17 |
AU2020220225A1 (en) | 2020-09-10 |
AU2016229268B2 (en) | 2020-09-10 |
IL254236A0 (en) | 2017-10-31 |
EP3265456A4 (en) | 2018-07-18 |
EA034891B1 (ru) | 2020-04-02 |
ES2838977T3 (es) | 2021-07-02 |
US10150732B2 (en) | 2018-12-11 |
KR20170125897A (ko) | 2017-11-15 |
PH12017501611A1 (en) | 2018-03-05 |
EP3265456A1 (en) | 2018-01-10 |
JP6697809B2 (ja) | 2020-05-27 |
CN107592861B (zh) | 2021-06-08 |
BR112017019150A2 (pt) | 2018-07-31 |
EP3265456B1 (en) | 2020-11-18 |
CN107592861A (zh) | 2018-01-16 |
KR102594441B1 (ko) | 2023-10-25 |
EA201791874A1 (ru) | 2018-01-31 |
EP3795568A1 (en) | 2021-03-24 |
US20170369443A1 (en) | 2017-12-28 |
US20200115341A1 (en) | 2020-04-16 |
US10570094B2 (en) | 2020-02-25 |
US11072585B2 (en) | 2021-07-27 |
CA2977947A1 (en) | 2016-09-15 |
MX2017011269A (es) | 2018-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL254236A0 (en) | Fluorine-converted lysyl oxidase-like 2 inhibitors and their uses | |
EP3265445A4 (en) | Lysyl oxidase-like 2 inhibitors and uses thereof | |
HK1243741A1 (zh) | 腫瘤壞死因子受體超家族(tnfrsf)結合劑 | |
IL255577B (en) | Binding materials - tigit and their uses | |
HUE065174T2 (hu) | HLA-alapú módszerek és készítmények, valamint azok felhasználása | |
EP3317258A4 (en) | LYSYL OXIDASE LIKE 2 INHIBITORS AND USES THEREOF | |
ZA201805805B (en) | Formulations and methods | |
GB201605126D0 (en) | Inhibitors and their uses | |
EP3325462A4 (en) | INHIBITORS OF LYSYL OXIDASE-LIKE 2 AND USES OF SAID INHIBITORS | |
IL256137B (en) | Corneal implant and its use | |
SG11201802658VA (en) | Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof | |
IL265232A (en) | Uses of lysyl oxidase-like inhibitor 2 | |
EP3572400C0 (en) | EZH2 INHIBITOR AND ITS USE | |
GB201706355D0 (en) | Methods compositions and uses relating thereto | |
EP3414229A4 (en) | CHINOLINE LYSYL OXIDASE LIKE 2 INHIBITORS AND USES THEREOF | |
GB201706356D0 (en) | Methods compositions and uses relating thereto | |
GB201706352D0 (en) | Methods compositions and uses relating thereto | |
GB201705091D0 (en) | Compositions and methods and uses relating thereto | |
GB201608762D0 (en) | Compositions and uses thereof | |
GB201715785D0 (en) | Methods compositions and uses relating thereto | |
PT3473677T (pt) | Composição de poliorganossiloxano curável e sua utilização | |
GB201705626D0 (en) | Compositions and methods | |
PL3429555T3 (pl) | Preparat mesny i jego zastosowanie | |
ZA201807665B (en) | Methods and compositions | |
GB201715820D0 (en) | Compositions and methods |